Final height of growth hormone-treated patients with growth hormone deficiency: the North American experience.
The results of treatment of growth hormone (GH)-deficient patients with recombinant GH are better than the results of treatment with pituitary GH. The reasons for this improvement include higher dosages, more consistent treatment, and daily administration. Under ideal circumstances, final height in patients with GH deficiency (GHD) can be within the normal range for adult height with GH treatment, and brought close to their target height. To achieve this result, it is important to diagnose and treat GHD early, use adequate doses of GH, and continue treatment until final height.
Hintz
R L
RL
Department of Pediatrics, Stanford University Medical Center, CA 94305, USA.
D000293:Adolescent; D000328:Adult; D001827:Body Height / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006130:Growth Disorders / Q000175:diagnosis / Q000188:drug therapy*; D013006:Growth Hormone / Q000008:administration & dosage; D019382:Human Growth Hormone / Q000008:administration & dosage* / Q000172:deficiency*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009656:North America; D012016:Reference Values; D016896:Treatment Outcome
D019382:Human Growth Hormone; D013006:Growth Hormone